Top Page
Fusion Antibodies Plc
(LSE:FAB)
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
Fusion Antibodies Plc Business Overview & Revenue Model
Fusion Antibodies Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60M | 1.97M | 1.14M | 2.90M | 4.80M | 4.17M |
| Gross Profit | 290.00K | 430.00K | -265.00K | 202.00K | 1.72M | 1.31M |
| EBITDA | -1.36M | -1.62M | -2.06M | -2.48M | -573.00K | -532.00K |
| Net Income | -1.47M | -1.71M | -2.23M | -2.60M | -1.20M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 1.81M | 1.32M | 2.42M | 2.06M | 4.92M | 5.83M |
| Cash, Cash Equivalents and Short-Term Investments | 252.00K | 359.00K | 1.20M | 195.00K | 2.05M | 2.69M |
| Total Debt | 388.00K | 20.00K | 43.00K | 75.00K | 69.00K | 230.00K |
| Total Liabilities | 1.09M | 654.00K | 627.00K | 939.00K | 1.23M | 1.08M |
| Stockholders Equity | 726.00K | 669.00K | 1.79M | 1.12M | 3.68M | 4.75M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -1.37M | -1.77M | -1.87M | -591.00K | -1.52M |
| Operating Cash Flow | -1.19M | -1.36M | -1.77M | -1.75M | -333.00K | -1.15M |
| Investing Cash Flow | -69.00K | -5.00K | 1.00K | -114.00K | -258.00K | -365.00K |
| Financing Cash Flow | 1.07M | 529.00K | 2.77M | 7.00K | -46.00K | 2.67M |
Fusion Antibodies Plc Technical Analysis
Fusion Antibodies Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £10.89M | -6.32 | -15.57% | ― | 13.32% | 55.07% | |
52 Neutral | £26.97M | -7.14 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £17.05M | -10.07 | -164.37% | ― | -11.43% | 23.40% | |
43 Neutral | £34.92M | -2.75 | -609.30% | ― | ― | ― | |
41 Neutral | £3.12M | -0.29 | ― | ― | 418.49% | 27.86% | |
38 Underperform | £9.87M | -0.25 | -407.49% | ― | 72.17% | 79.03% |
Fusion Antibodies Plc Corporate Events
Fusion Antibodies has reported that the US National Cancer Institute (NCI) wishes to continue using the company’s OptiMAL® human antibody discovery platform as a frontline technology for a range of targets, following a validation project that ran from late 2023 into this year. NCI has submitted a proposal to extend the existing collaboration agreement to cover screening of several specified targets, and discussions held at a recent industry conference in San Diego explored not only support for immediate screening needs but also potential additional projects that could carry enhanced ownership benefits for Fusion. The company cautioned that negotiations around the expanded programme are expected to run into early 2026 and will be subject to lengthy formal approval processes at the US National Institutes of Health, meaning there is no certainty an extension will be concluded or on what terms, but management framed NCI’s interest as a strong validation of OptiMAL® and an encouraging sign for Fusion’s positioning in antibody discovery services.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc has officially launched its OptiMAL® Human Antibody Discovery platform, which was unveiled at the Antibody Engineering and Therapeutics conference in San Diego. This platform, protected by a US patent, utilizes a synthetic library of antibody sequences and Mammalian Display technology to discover novel human antibodies, potentially accelerating the development of therapeutic antibodies and strengthening Fusion’s position in the antibody discovery industry.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc announced the upcoming commercial launch of its OptiMAL® Human Antibody Discovery platform, which integrates its Mammalian Display technology with the Opti-library to discover novel human antibodies. The technology boasts a high transduction efficiency of over 70% and supports large libraries exceeding 10⁹ variants, offering significant advantages over competitor platforms. This development positions Fusion Antibodies as a leader in the pre-clinical antibody discovery industry, potentially enhancing its market presence and stakeholder value.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £15.00 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc reported a reduction in losses and increased R&D expenditure in its interim results for the first half of FY2026, despite a decrease in revenue compared to the previous year. The company highlighted significant progress with its OptiMAL® platform, including a successful validation project with the National Cancer Institute and the granting of a US patent. The commercial launch of OptiMAL® is on track, with positive feedback from prospective clients, indicating potential for a scalable licensing-based business model. Fusion Antibodies is well-positioned to capitalize on a recovering market and aims to expand its offerings to include additional libraries for diagnostics and veterinary medicine.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc announced it will release its unaudited interim results for the six months ended 30 September 2025 on 24 November 2025. The company will host an online live presentation for investors on 25 November 2025, providing an opportunity for stakeholders to engage with the management team and receive updates on the company’s business and current trading. This announcement underscores Fusion’s commitment to transparency and investor engagement, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc has released a video featuring Dr. Richard Buick, CSO, discussing the science and technology behind their OptiMAL® library, which is set to launch commercially in December 2025. The OptiMAL® library, protected by a US patent, is designed to discover novel human antibodies and is part of the company’s strategy to provide innovative platforms that accelerate drug development, potentially enhancing their market position and offering significant benefits to stakeholders in the pharmaceutical and diagnostic industries.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc announced the successful validation of its OptiMAL® platform for isolating specific antibodies against both protein and peptide targets, marking a significant milestone in its collaboration with the National Cancer Institute. This development positions the company for the commercial launch of OptiMAL® in December 2025 and expands its market potential by enabling the use of the platform for a wider range of targets. The NCI has expressed interest in extending its agreement with Fusion, highlighting the platform’s potential as a leading tool in therapeutic antibody discovery.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £14.00 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc announced that all resolutions were passed at its recent annual general meeting. This development underscores the company’s stable governance and continued focus on advancing its strategic goals in the rapidly growing monoclonal antibody therapeutics market, which is projected to surpass $445 billion by 2028.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc reported a decrease in unaudited revenues for the first half of the financial year 2026 compared to the previous year, but an increase from the second half of 2025, with improved gross margins reflecting operational efficiency. The company achieved a significant milestone with a US patent for its OptiMAL® library design and continued its collaboration with the National Cancer Institute, which plans to use the platform for future projects. Fusion secured new contracts, including a stable cell line development for a US biotechnology company and multiple humanization projects, strengthening its industry position. The company anticipates a stronger performance in the second half of the year, supported by a robust order book and promising sales opportunities, and is on track with strategic goals, including the launch of OptiMAL® in December.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc has secured a new multi-target Integrated Therapeutic Antibody Services project with a European-based global pharmaceutical company. This project, which involves humanizing VHH antibody fragments, underscores Fusion’s strategic focus on partnering with major pharmaceutical firms to drive sustainable growth and enhance market positioning. The project is expected to be completed within the current financial year, generating revenues of at least £175,000, and highlights Fusion’s capability to deliver high-quality, innovative solutions.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.